These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
166 related items for PubMed ID: 17099725
1. Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis. Nilsson LM, Keller UB, Yang C, Nilsson JA, Cleveland JL, Roussel MF. Oncogene; 2007 May 03; 26(20):2833-9. PubMed ID: 17099725 [Abstract] [Full Text] [Related]
2. Nfkb 1 is dispensable for Myc-induced lymphomagenesis. Keller U, Nilsson JA, Maclean KH, Old JB, Cleveland JL. Oncogene; 2005 Sep 15; 24(41):6231-40. PubMed ID: 15940251 [Abstract] [Full Text] [Related]
3. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Nilsson JA, Keller UB, Baudino TA, Yang C, Norton S, Old JA, Nilsson LM, Neale G, Kramer DL, Porter CW, Cleveland JL. Cancer Cell; 2005 May 15; 7(5):433-44. PubMed ID: 15894264 [Abstract] [Full Text] [Related]
5. MIF loss impairs Myc-induced lymphomagenesis. Talos F, Mena P, Fingerle-Rowson G, Moll U, Petrenko O. Cell Death Differ; 2005 Oct 15; 12(10):1319-28. PubMed ID: 15947793 [Abstract] [Full Text] [Related]
7. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Yu D, Thomas-Tikhonenko A. Oncogene; 2002 Mar 14; 21(12):1922-7. PubMed ID: 11896625 [Abstract] [Full Text] [Related]
9. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, Han SS, Tae Chung S, Torrey TA, Cheung WC, Polakiewicz RD, McNeil N, Ried T, Mushinski JF, Morse HC, Janz S. Cancer Res; 2005 Feb 15; 65(4):1306-15. PubMed ID: 15735016 [Abstract] [Full Text] [Related]
10. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV. Zörnig M, Grzeschiczek A, Kowalski MB, Hartmann KU, Möröy T. Oncogene; 1995 Jun 15; 10(12):2397-401. PubMed ID: 7784089 [Abstract] [Full Text] [Related]
11. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development. van Veelen W, van Gasteren CJ, Acton DS, Franklin DS, Berger R, Lips CJ, Höppener JW. Cancer Res; 2008 Mar 01; 68(5):1329-37. PubMed ID: 18316595 [Abstract] [Full Text] [Related]
17. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Genes Dev; 1999 Oct 15; 13(20):2658-69. PubMed ID: 10541552 [Abstract] [Full Text] [Related]
18. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues. Ramsey MR, Krishnamurthy J, Pei XH, Torrice C, Lin W, Carrasco DR, Ligon KL, Xiong Y, Sharpless NE. Cancer Res; 2007 May 15; 67(10):4732-41. PubMed ID: 17510401 [Abstract] [Full Text] [Related]
19. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, Pandolfi PP. Nat Med; 2004 May 15; 10(5):484-6. PubMed ID: 15098029 [Abstract] [Full Text] [Related]
20. Chemoprevention of B-cell lymphomas by inhibition of the Myc target spermidine synthase. Forshell TP, Rimpi S, Nilsson JA. Cancer Prev Res (Phila); 2010 Feb 15; 3(2):140-7. PubMed ID: 20103729 [Abstract] [Full Text] [Related] Page: [Next] [New Search]